1. MR1 inhibits anti-MTg autoantibody responses in CD28−/− NOD
MR1 inhibits anti-MTg autoantibody responses in CD28−/− NOD.H-2h4 mice but increases autoantibody responses in PD-1−/− NOD.H-2h4 mice.
MR1 inhibits anti-MTg autoantibody responses in CD28−/− NOD.H-2h4 mice but increases autoantibody responses in PD-1−/− NOD.H-2h4 mice. (A) Anti-MTg autoantibodies were measured in individual CD28−/− mice from Fig. 1A (n = 15). (B) Anti-MTg autoantibodies [isotype control (0–2) n = 20, MR1 (0–2) n = 7, isotype control (3–5) n = 18, MR1 (3–5) n = 23] were measured in individual 16–20-wk-old PD-1−/− NOD.H-2h4 mice from Fig. 3A. Mice were separated into two groups based on their ATD severity scores (0–2+ or 3–5+). (C) Anti-La autoantibodies (WT n = 7, isotype control n = 10, MR1 n = 12) and anti-Ro autoantibodies (WT n = 6, isotype control n = 9, MR1 = 9) were measured in some 18–20-wk-old PD-1−/− female mice from Fig. 3A. *p < 0.05, **p < 0.001, ***p <
Elisaveta Voynova et al. ImmunoHorizons 2018;2:54-66
Copyright © 2018 The Authors